T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR
- PMID: 35245466
- DOI: 10.1016/j.stem.2022.02.002
T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR
Abstract
Fibrosis, or chronic fibroblast activation and extracellular matrix deposition, underlies most cardiovascular diseases and remains challenging to target therapeutically. Reported in Science by Rurik et al., modified mRNA technology can reprogram endogenous T cells into fibroblast-ablating CAR-Ts in mouse hearts, offering a promising and tractable immunotherapy approach for tackling fibrosis.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.A.M. is on the scientific advisory boards of Artemes Bio and Eikonizo Therapeutics, received funding from Italfarmaco for an unrelated project, and has a subcontract from Eikonizo Therapeutics related to an SBIR grant from the National Institutes of Health (HL154959).
Comment on
- 
  
  CAR T cells produced in vivo to treat cardiac injury.Science. 2022 Jan 7;375(6576):91-96. doi: 10.1126/science.abm0594. Epub 2022 Jan 6. Science. 2022. PMID: 34990237 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
 
        